A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects

Trial Profile

A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2016

At a glance

  • Drugs Epratuzumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions
  • Acronyms EMBODY4
  • Sponsors UCB; UCB Pharma Inc
  • Most Recent Events

    • 14 Mar 2016 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 02 Aug 2013 Planned End Date changed from 1 Feb 2016 to 1 Jan 2019 as reported by ClinicalTrials.gov.
    • 21 Mar 2012 Additional trial locations added as reported by Australian New Zealand Clinical Trials Registry record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top